The results of the multicentre, randomized, controlled trial to test the effectiveness of decompressive craniectomy in adults with traumatic brain injury and high intracranial pressure (Decompressive Craniectomy, DECRA) were published in 2011. DECRA concluded that decompressive craniectomy decreased intracranial pressure (ICP) but was associated with more unfavourable outcomes. Our review aims to put the DECRA trial into context, comment on its findings and discuss whether we should include decompressive craniectomy in our clinical armamentarium.
INTRODUCTION
Traumatic brain injury (TBI) is a major health problem worldwide. The long-term effects of severe TBI are a continual challenge to health systems and a burden on families and the community in terms of monetary cost, suffering and disability [1] . Recent studies have shown that the number of patients with an unfavourable outcome after severe TBI is still very high, even in highly specialized centres. Analysis of the International Mission for Prognosis and Clinical Trials (IMPACT) database shows that mortality in severe TBI has significantly dropped in the last decade, but that at least 50% of affected patients continue to die or have a nonfunctional outcome despite they were managed in centres with expertise in their management [2] . In this grim scenario, drugs that were promising in preclinical studies have yielded disappointing results when tested in randomized clinical trials (RCTs) [3] .
For the last two decades, clinicians have been showered with promises that the 'magic bullet' for improving TBI outcome was just around the corner. Pharmaceutical companies have spent a large part of their resources in the field of neuroprotection. However, no RCT has presented positive results and progress in TBI research -mostly industrysponsored -has lost momentum. For clinicians and families, advancements are painfully slow. Given this scenario, it is easy to understand the hype and controversy created by the long-awaited results of the Decompressive Craniectomy (DECRA) ]. The disappointing results of DECRA provoked strong emotional reactions, both in neurosurgeons and intensivists, and the methods and results of the trial are under heavy scrutiny to explain the confounding lack of positive results. This scenario is not new and reminds many of us of the similar controversy sparked by the results of the hypothermia trial published in the same journal in 2001 [5] .
In times of rigid reliance on evidence-based medicine, the immediate reaction of some clinicians has been to rule out decompressive craniectomy, even as a rescue option in refractory high ICP. As clinicians await the results of the second RCT on decompressive craniectomy in TBI, the RescueICP trial, the debate on how to proceed is fuelled with many opposing positions published in letters, editorials and articles. Our review aims to put the DECRA trial into context, comment on its findings and discuss whether we should include decompressive craniectomy in our clinical armament until more conclusive empirical evidence is available.
Is increased intracranial pressure still a relevant problem in severe traumatic brain injury?
In the early 1990s, high intracranial pressure (ICP) was considered the most frequent cause of death and disability after severe TBI [6] . Although thresholds are not consistent, high ICP is usually defined as being above 20 mmHg. The cause of high ICP is always an increase in the intracranial volume produced by an increase in brain water (oedema), cerebrospinal fluid, cerebral blood volume and/or mass lesions.
The risk of developing high ICP can vary greatly depending on the methodology used and in which Marshall classification category the patient is included [7] . Different studies use different methods to summarize episodes of increased ICP, such as the time periods above a certain threshold, mean ICP, the standardized area under the curve, the percentage of time above a threshold or the percentage of patients requiring second-tier therapeutic measures. Thus, the true incidence of high ICP is notoriously unreliable. This problem became evident in the dexanabinol study in which only 10% of patients had ICP above 25 mmHg [8] , whereas in the Traumatic Coma Data Bank (TCDB), 72% of the patients had an ICP above 20 mmHg. A possible reason for this difference is that half of the patients in the dexanabinol study had a diffuse brain injury type II, but only 24% of patients were classified in this category in the TCDB [6] . This low incidence of high ICP is consistent with both our data and that of the DECRA study, which included only 155 of the 3478 patients screened for eligibility (4.5%) [4 && ]. The reasons for the lower incidence of refractory high ICP may have been better resuscitation strategies, better and faster transport to the referral centres, and a much more aggressive treatment of the mass lesions. The role of high ICP is also unclear in the most recent megastudies, CRASH and IMPACT; models used to predict outcome did not include ICP in the multivariate analysis, but both models used age, Glasgow motor response, pupil reactivity and some characteristics of the initial computed tomography (CT) scan as input variables [9 && ]. In contrast with these puzzling data, Juul et al. [10] showed in a posthoc analysis of the data from the multicentre Selfotel trial that the most powerful predictor of neurological worsening -occurring in 27% of the patients -was the presence of intracranial hypertension (ICP!20 mmHg), either initially or during neurological deterioration. When ICP increases and is not controllable, most patients progress to brain death.
How is high intracranial pressure managed?
The treatment of high ICP is generally based on the guidelines developed by the Brain Trauma Foundation (BTF). In the most recent version, the recommendation (level II) was to start treatment when ICP rises above 20 mmHg [11] . The most widely used protocol for treating high ICP is based on an algorithm published in the first version of the guidelines that was removed in the newest 2007
KEY POINTS
The DECRA study showed that decompressive craniotomy does not improve outcome in patients with severe TBI who were selected for decompressive craniectomy based on an intracranial pressure threshold of 20 mmHg.
To verify or refute the conclusions of the DECRA study, an adequately powered randomized clinical trial should be conducted.
Decompressive craniotomy might be used in patients with severe TBI and high ICP refractory to first and/or second level therapeutic measures.
The thresholds used in future studies on the effectiveness of decompressive craniectomy should probably be increased. There is a lack of equipoise among intensivists and neurosurgeons in terms of whether to include patients with intracranial pressure at the 20-mmHg threshold in a randomized clinical trial.
version. Because the terminology 'first-and secondtier manoeuvres' is firmly ingrained in TBI literature, we have used it in this review for the sake of clarity.
When ICP remains above 20 mmHg despite the implementation of a set of general measures (head elevation, normothermia, volume resuscitation, sedation, etc.), a group of first-line therapies, including CSF drainage, muscular paralysis, moderate hypocapnia ( pCO 2 30-35 mmHg) and mannitol or hypertonic saline administration, are started [11] . When first-level measures fail to control ICP, only a few second-tier therapies are available unless potentially evacuable mass lesions are detected in the CT scan. Suggested second-tier measures are high-dose barbiturates or propofol, intense hyperventilation ( pCO 2 <30 mmHg), increasing mean arterial blood pressure, mild or moderate hypothermia and decompressive craniectomy. Of these, only barbiturates and propofol are included in level II recommendations [11] . However, a Cochrane systematic review concluded that barbiturates may reduce ICP but do not reduce mortality or improve outcome in severe TBI survivors [12] . Because of the lack of effective second-level medical therapies, decompressive craniectomy has been reconsidered in the treatment of refractory high ICP.
A historical background of decompressive craniectomy Kocher [13] was the first to propose decompressive craniectomy in patients with clinical symptoms of elevated ICP in 1901. Decompressive craniectomy is performed in two different situations: first, prophylactic decompression, or primary decompressive craniectomy, which is carried out on patients undergoing surgery and the surgeon decides to leave the bone out on the basis of the CT scan and/or intraoperative surgical findings ('tight' brain or difficulties in repositioning the bone flap) [14] , and second, secondary decompressive craniectomy, when the procedure is performed in patients in whom high ICP is refractory to medical treatment. Despite the ongoing debate about its use, the techniques used in decompressive craniectomy vary too widely among neurosurgeons and are based on the surgeons' preferences rather than adherence to standards or professional consensus. These variations include small to massive amounts of bone removal, unilateral or bilateral bone decompression, opening the duramater or leaving it closed, and sectioning of the falx, among others. The variation in neurosurgeons' overall practices has created difficulty when comparing the results of published studies. However, a recent meta-analysis that included retrospective and nonrandomized studies showed that decompressive craniectomy is clearly effective in reducing ICP [15 && ].
The evidence before the Decompressive Craniectomy trial
In the last decade, there has been an ongoing debate about the role of secondary decompressive craniectomy in the management of high ICP. A Cochrane systematic review updated in 2008 concluded that there was no evidence to support the routine use of decompressive craniectomy to reduce unfavourable outcomes in adults with TBI and refractory high ICP [14] . However, the same review concluded that decompressive craniectomy could be an option in the paediatric population when maximal medical treatment fails to control ICP. This recommendation was based on a single RCT published by Taylor et al. [16] in which patients were eligible for randomization if they were aged below 18 years, underwent ICP monitoring and developed high ICP during the first day after admission. The main limitations were that only 27 patients were randomized -13 assigned to decompressive craniectomyand that a bitemporal craniectomy was conducted, but the duramater was not opened. The risk of death in the decompressive craniectomy arm was lower than in patients treated with maximal medical treatment [relative risk (RR) 0.54, 95% confidence interval (CI) 0.17-1.72], and the risk of an unfavourable outcome (death, vegetative state or severe disability) was also lower in the decompressive craniectomy group.
In 2009, Qiu et al. [17] presented the results of an RCT comparing two unilateral decompressive procedures in adults with severe TBI and posttraumatic brain swelling. It is difficult to identify the eligibility criteria of this study; patients with a diffuse injury type IV (Marshall classification) were eligible, but in the Results section, patients with categories III-VI were also included. The only conclusion that can be extracted from this trial is that large unilateral craniotomies are significantly superior to smaller ones. 
Deconstructing the Decompressive Craniectomy study
In the DECRA study, 3478 patients were assessed for eligibility and only 155 were enrolled (4.5%). Seventy-three patients were randomized to decompressive craniectomy and 82 were assigned to standard care. The baseline characteristics of the two groups were well balanced with the unlucky exception of the number of patients with bilateral unreactive pupils, which was significantly higher in the decompressive craniectomy group (27%) than in the control group (12%). Median ICP during 12 h before randomization was 20 mmHg in both arms. After randomization, mean ICP was significantly lower in the decompressive craniectomy group (14.4 vs. 19.1 mmHg, P < 0.001). Despite the significant reduction in the duration of mechanical ventilation and days in the ICU, decompressive craniectomy increased the likelihood of a poor outcome. Unfavourable outcomes occurred in 51 patients (70%) in the decompressive craniectomy group and in 42 patients (51%) in the control group. However, these differences in outcome vanished after adjusting the results for the pupillary reactivity covariate. After adjustment, there were no statistically significant differences in the dichotomized 6-month outcome. Other relevant issues that the reader should take into consideration in DECRA include:
(1) Surgical technique: In our opinion, the surgical technique used in the DECRA study was suboptimal. The authors used a modified version of the decompressive procedure described by Polin et al. [18] , who stated that sectioning of the falx was important because it 'allowed a further vector of anterior expansion'. In DECRA, decompressive craniectomy was performed without falx sectioning, and thus, decompressive surgery was incomplete, as shown in the operative photography presented (Figure 4 , online appendix). The potential complications involving herniations of the injured brain through small dural openings are, in our opinion, a serious concern. (2) ICP threshold: The ICP threshold in DECRA, 20 mmHg for 15 min, was too low and would probably cause a lack of equipoise in many institutions wherein randomizing a patient at such an early stage is not an acceptable option. Servadei [19 & ] states that 'most neurosurgeons and intensivists dealing with TBI will not consider decompressive craniectomy in patients who have an intracranial pressure of around 20 mmHg for such a short time'. (3) Evaluation of outcome: The DECRA trial employed the traditional approach of evaluating outcome by using a dichotomized extended version of the GOS (GOSE) into favourable and unfavourable categories. The shortcomings of dichotomizing GOSE have been extensively discussed by Murray et al. [20] , who proposed the 'sliding dichotomy approach' as an alternative, a method that takes into consideration the baseline characteristics of the patient at randomization and, to quote Murray et al. [20] , 'instead of taking a single definition of 'good' outcome for all patients, the definition is tailored to each individual patient's baseline prognosis on entry to the trial'.
In summary, we believe that the key message that any unbiased reader will take away from DECRA is that with the proposed surgical procedure, decompressive craniectomy significantly lowers ICP, reduces the number of days of mechanical ventilation and shortens the length of stay in the ICU. However, neither mortality nor unfavorable outcome is reduced when adjusting the significant baseline covariates that were unbalanced between groups. Therefore, the conclusion made by these authors in the abstract in which they state that decompressive craniectomy 'was associated with more unfavorable outcomes' is at the very least misleading, and not supported by the results of the study.
Are the Decompressive Craniectomy study results valid?
Although RCTs are the gold standard for evidencebased medicine, it is well established that their external validity must be analysed. The patients enrolled are frequently not reflective of those seen in real-life practice. Steg et al. [21] showed in a pooled analysis of three RCTs involving patients with an acute myocardial infarction that despite having been treated at the same hospitals during the same period, enrolled patients differed markedly in their baseline characteristics and outcomes from patients who would have been eligible for inclusion but were not enrolled, in addition to differing from ineligible patients [21] .
Unfortunately, randomization in DECRA did not achieve balanced groups in one of the most significant covariates, pupillary reactivity. Bilateral unreactive pupils were present at baseline in 27% of the patients in the decompressive craniectomy arm but only in 12% of patients in the control group [22] . The recent CRASH and IMPACT calculators, available online [22, 23] , can be used to simulate outcome prediction. We used the data from one of the patients published by Göksu et al. [24 && ], who reported outcomes in patients with bilateral nonreactive dilated pupils who underwent decompressive craniectomy. Case 11 was a 54-year-old woman with a GCS score of 7 on admission that deteriorated to 4. The CT scan showed a left subdural hematoma, bilateral contusions, diffuse cerebral swelling and a 10-mm midline shift. According to the CRASH model, this patient had a risk of unfavourable outcome at 6 months of 96.8%, and a similar prediction (94%) was made using the IMPACT calculator. If the same patient's pupils were evaluated as reactive in both eyes, the risk of an unfavourable outcome would have been reduced by 10% in both CRASH and IMPACT models. However, this particular patient showed a good recovery in terms of GOS score 1 year after injury. Although anecdotal, this patient simulation reminds us of the importance of the serious imbalance in baseline covariates that may occur, regardless of any adjustments made in the analysis. A second factor to consider is that even the most sophisticated models to predict outcome can fail when applied to specific patients.
If we accept that DECRA was just one more trial with negative results, the issue of statistical power must also be discussed. We calculated the sample size required in this study using GÃPower 3.1.4 [25] , with the hypothetical aim of detecting a 10% decrease in 1-year unfavourable outcome in patients treated with decompressive craniectomy making the following assumptions: a power of 80%; a two-tail calculation; an alpha error of 0.05; an effect size of 0.20; and no patients lost in the follow-up. In this crude simulation, the number of patients required was 321, randomized in a 1-to-1 ratio. Therefore, DECRA was clearly underpowered to show a lack of effectiveness of decompressive craniectomy in improving unfavourable outcome.
The ethical debate over decompressive craniectomy
Regardless of whether RescueICP will put to rest any doubts regarding the effectiveness of decompressive craniectomy to improve outcome, there are other pending debates about complex issues, such as the futility of treatment and the quality of life (QoL) of survivors. This ethical dilemma is always present when life-saving procedures are used in medicine and undesirable outcomes can occur. The debate about who must decide if and when a particular treatment is futile has already started in malignant infarction, where class I evidence showing that decompressive craniectomy significantly reduces mortality is already available [26] . For a comprehensive overview of this topic in TBI, we recommend the studies by Honeybul et al. The question of whether a patient may wish to survive severely disabled is very subjective and is usually answered by the caregivers [29] . On the contrary, as Honeybul et al. [27 && ] write, it is a very well known fact that many people 'do adapt to unfortunate events in life by ''re-calibrating'' and learning to accept a degree of disability they would previously have judged as unacceptable'. We feel that, ideally, well defined criteria should be used to decide when it is appropriate to withhold treatment from severe TBI patients. Without these criteria, the attitudes and prejudices of individual doctors will tend to exert an undue influence on such decisions. Neurosurgeons and intensivists must be prepared to participate in what will no doubt continue to be a lively debate among patients, caregivers, institutions, regulatory agencies and society as a whole.
CONCLUSION
Despite the negative findings of DECRA, the claim that decompressive craniectomy increases unfavourable outcome is overstated and not supported by the data presented. We believe that it is premature to change clinical practice and that decompressive craniectomy should not be disregarded in certain patients with high ICP refractory to first-line therapeutic measures. Given the dismal outcome in these patients, it is reasonable to include this technique as a last resort in any type of protocoldriven management when conventional therapeutic measures have failed, the presence of operable masses has been ruled out and the patient may still have a chance of a functional outcome. The main lesson to be learned from this study is that an upper threshold for ICP must be used as a cutoff for decompressive craniectomy candidates. For definitive answers, additional RCTs are required to identify which patients can benefit from this procedure.
